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Introduction
The development of this series of articles arose from cases, the authors have also provided a summary algo-
two different perspectives. The rationale for the topic rithm for patient management of his or her particular GN
was derived from a survey of learning needs of Canadian type. It must be remembered that none of these ratings
nephrologists done in the fall of 1995 [1]. The manage- supersede the nephrologists’ clinical judgment based on
ment of glomerulonephritis (GN) ranked number 1 out the individual patient’s specific requirements. Certain
of 18 options in terms of both the nephrologists’ interest circumstances may take precedence over even grade A
and their specific educational needs. The other perspec- recommendations. Also, note that these recommenda-
tive was the renewed interest in the development of tions are based on information in the literature as of the
clinical guidelines based on peer review of published end of 1998, and new evidence will need to be incorpo-
data. The latter prompted us to present the information rated into these guidelines as it emerges.
in an evidence-based format. The definitions used for The first article in this series addresses the major com-
establishing the levels of evidence and the grade of rec- mon elements of management in the progressive glomer-
ommendation are a synthesis from a number of sources, ular-based diseases (that is, blood pressure control, the
but closely adhere to the those set out in the clinical choice of antihypertensive agents, and the issue of dietary
guidelines section for rating treatment trials by the Cana- protein restriction). Each subsequent article focuses on
dian Hypertensive Society Consensus Conference [2]. a specific primary type and delineates for the readership
Each author was charged with reviewing all of the litera- the highest level of evidence that supports the specific
ture of their assigned histological type that emphasized grade of recommendation for therapy. The goal is to pro-
therapy, with a restriction to studies in adults with primary vide a succinct, yet complete and fully referenced, evi-
GN. The exception to the age limitation was in minimal dence-based approach to treatment. As the individual
change disease because the best trials in that type have projects matured, we realized that clear and precise ther-
been done in children. The articles selected for inclusion apeutic approaches with grade A recommendation based
were the best available and were subsequently rated by on level 1 studies in each type were often lacking and that
each author as to their quality, as defined by the levels a wide variation of studies exists in the literature in regard
of evidence guidelines outlined in Table 1. to therapy. The data ranged from multiple randomized,
The specific treatment recommendations for each type controlled trials in minimal change disease to their virtual
of glomerular disease were then graded by each author absence in focal segmental glomerulosclerosis (FSGS).
according to the level of evidence in these reviewed stud- The subsequent application of a uniform scoring system
ies. The grading systems for the final recommendations to these data resulted in an equally broad range in the
are given in Table 2. All authors agreed to present the grade given to each of the recommended therapies by
information in a uniform manner and to use similar ter- the authors. For example, a randomized, controlled trial
minology throughout the series. This was to ensure that, has not been done that compares corticosteroids to pla-
although each article was structured to stand alone, by cebo in primary idiopathic FSGS, yet Dr. Burgess still
following the same format, a clear and logical approach made her number one recommendation long-term corti-
to all types would be provided to the reader. Each article costeroid therapy. She supported her choice based on
begins with an abstract describing the overall recommen- several large but retrospective level 4 and level 5 quality
dations followed by the studies that support the treat-
reports; however, she lets the readership know that the
ment options. This is followed by a standardized set of
overall evidence for this therapy is weak, as indicatedtables that outline the details of the chosen references,
by her D grade recommendation.including the number of patients in each study, the treat-
Some of the reviews were limited in other ways, forments used, the outcomes, and the authors’ overall rating
instance, because of the discovery of new etiologicalwith regards to the level of evidence achieved. In many
agents. Recent data, for example, have linked membrano-
proliferative GN to hepatitis C. This information throws
Key words: glomerulonephritis, clinical guidelines, treatment trials, into question even the best of randomized, controlledminimal change disease, end-stage renal disease.
trials in this type of glomerular disease because they
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Table 1. Levels of evidence for rating studies of treatment, sons of treatment efficacy across studies prone to serious
prevention and quality assurance
errors [8]. Properly designed prospective clinical trials
1. A randomized-controlled trial (RCT) that demonstrated a statisti- in many of the types reviewed are still required, and this
cally significant difference in at least one important outcome (for series will hopefully serve to highlight this need. Despiteexample, survival or major illness).
these limitations and difficulties, each of the authors hasOR
If the difference is not statistically significant, an RCT of adequate provided recommendations for management that are as
sample size to exclude a 25% difference in relative risk with 80% clear as possible, based on the best evidence in the litera-power, given the observed results.
ture. I am delighted to have been asked to edit such a
2. An RCT that does not meet the level 1 criteria.
series and hope that you will find the articles useful in
3. A non-randomized trial with contemporaneous controls selected by
the management of your patients with primary GN.some systematic method (that is, not selected by perceived suitability
for one of the treatment options for individual patients).
Daniel C. CattranOR
Guest EditorSubgroup analysis of a randomized trial.
4. A before-after study or case series (of at least 10 patients) with Reprint requests to Daniel C. Cattran, M.D., The Toronto Hospital,
historical controls or controls drawn from other studies. General Division, CCRW3-884 101 College Street, Toronto, Ontario
M5G 1 l7, Canada.5. Case series (of at least 10 patients) without controls.
6. Case reports (fewer than 10 patients).
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